NINTEDANIB FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - INITIAL CLINICAL EXPERIENCE IN A UK COHORT

被引：4
|
作者：
Fletcher, S. V. [1 ]
Jones, M. G. [1 ]
Renzoni, E. [2 ]
Parfrey, H. [3 ]
Hoyles, R. [4 ]
Spinks, K. [5 ]
Kokosi, M.
Kwok, A. [6 ]
Warburton, C. [6 ]
Titmuss, V. [5 ]
Maher, T. [2 ]
Chua, F. [2 ]
Wells, A. [2 ]
Richeldi, L. [1 ]
Spencer, L. G. [6 ]
机构：
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] Royal Brampton Hosp, ILD Unit, London, England
[3] Papworth Hosp, Cambridge CB3 8RE, England
[4] John Radcliffe Hosp, Oxford, England
[5] Queen Alexandra Hosp, Portsmouth, Hants, England
[6] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England
来源：
THORAX | 2015年 / 70卷
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1136/thoraxjnl-2015-207770.146
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P9
引用
收藏
页码：A78 / A78
页数：1
相关论文
共 50 条
  • [31] Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
    Rivera-Ortega, Pilar
    Hayton, Conal
    Blaikley, John
    Leonard, Colm
    Chaudhuri, Nazia
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [32] Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Fell, Charlene D.
    Huggins, J. Terrill
    Nunes, Hilario
    Sussman, Robert
    Valenzuela, Claudia
    Petzinger, Ute
    Stauffer, John L.
    Gilberg, Frank
    Bengus, Monica
    Wijsenbeek, Marlies
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [33] Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
    Kato, Motoyasu
    Nakamura, Takahiro
    Kono, Kana
    Haraguchi, Mizuki
    Yamada, Tomoko
    Ihara, Hiroaki
    Takahashi, Fumiyuki
    Takahashi, Kazuhisa
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [34] Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
    Ochi, Yusuke
    Kato, Motoyasu
    Fujioka, Masahiro
    Hayashi, Mika
    Takagi, Haruhi
    Takahashi, Kazuhisa
    RESPIROLOGY CASE REPORTS, 2020, 8 (07):
  • [35] Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
    José Antonio Rodríguez-Portal
    Drugs in R&D, 2018, 18 : 19 - 25
  • [36] Pirfenidone and Nintedanib Therapy for Idiopathic Pulmonary Fibrosis: A Tertiary Centre Experience
    Diab, N.
    Mao, T.
    Danoff, S. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [37] Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
    Brunnemer, Eva
    Waelscher, Julia
    Tenenbaum, Svenja
    Hausmanns, Julia
    Schulze, Karen
    Seiter, Marianne
    Heussel, Claus Peter
    Warth, Arne
    Herth, Felix J. F.
    Kreuter, Michael
    RESPIRATION, 2018, 95 (05) : 301 - 309
  • [38] Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience (vol 36, pg 465, 2019)
    Udwadia
    LUNG INDIA, 2021, 38 (03)
  • [39] TREATMENT COST COMPARISON OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Ho, R.
    Rufino, C.
    Lisondo, C.
    Alves, M.
    VALUE IN HEALTH, 2017, 20 (09) : A893 - A893
  • [40] Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
    Bonella, Francesco
    Stowasser, Susanne
    Wollin, Lutz
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6407 - 6419
12345